Navigation Links
Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
Date:7/22/2009

The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow AgroSciences, Sigma-Aldrich Corporation, Genentech and Pfizer. For more information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
2. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
3. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
6. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
7. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
8. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
11. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... The Kansas City Animal Health Investment ... health companies to hear from animal health companies with the newest technology. Companies ... agreements or distribution contracts. This meeting is one of the only investment ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Jennerex, Inc. (San Francisco, CA,and Ottawa, Canada) a ... Reviews Cancer, has published an article about,the company,s ... encouraging clinical and preclinical data. The article,published ... David H. Kirn, M.D.,president and chief executive officer ...
... Will Continue to Fuel Growth and Generate CashNEW YORK, Feb. ... President James C. Borel said today he expects DuPont business ... by at least 1 to 2 points in 2009 and ... Agriculture & Nutrition segment an average of at least 15 ...
... 10 , - Nerviano ... the CDC7,Inhibitor , Nerviano Medical ... to conduct for the first time clinical trials of ... that is responsible for,the uncontrolled proliferation of cancer cells. ...
Cached Biology Technology:Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 2Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers 2
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... the Andes mountains of Ecuador have described a new plant ... itself a mini biodiversity hotspot. The new species, Piper ... insect species, most of which are entirely dependent on this ... larger project which focuses on the influence of plant-produced chemical ...
... factory built of gel does not sound very durable. But ... University do not have to last. They will actually ... medicine is required and they will gradually dissolve and ... The prospects are so enormous that Associate Professor of ...
... that generates the most scientific debate is the dating of ... the Spanish National Research Centre for Human Evolution, among others, ... , Journal of Archaeological Science , has clarified that the ... Homo antecessor were discovered in 1994, is 900,000 years ...
Cached Biology News:New plant species a microcosm of biodiversity 2Tiny soft medicine factories 2Dating is refined for the Atapuerca site where Homo antecessor appeared 2